

Susceptibility to BK polyomavirus-associated hemorrhagic cystitis in children undergoing allogeneic transplant

BK polyomavirus (BKPyV) detected after hematopoietic stem cell transplant (HSCT) is associated with hemorrhagic cystitis.¹ Cystitis causes dysuria, and may lead to urinary obstruction and an increased risk of death.² We prospectively studied 193 children and young adults at 2 large pediatric centers, and observed that BKPyV was frequently detected in the urine (viruria=87%) and blood (DNAemia=50%) after allogeneic HSCT, but only 22% developed cystitis.³ Reported risk factors for cystitis include cyclophosphamide, busulfan, mismatched human-leukocyte antigen (HLA) grafts, DNAemia, log-fold increases in viruria, and delayed immune reconstitution.² However, the exact mechanisms leading to BKPyV-associated cystitis, and the reasons why only some patients with BKPyV develop cystitis, are unknown. We hypothesized that host factors would be associated with cystitis and focused on polymorphisms in innate viral defense proteins including apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3 (APOBEC3),⁴ and toll-like receptor 3 (TLR3).⁵ To test our hypothesis, we analyzed stored blood samples from our existing cohort.

Our cohort of 193 subjects, ≥ 2 years old, were prospectively enrolled before allogeneic HSCT at the Children's Hospital of Philadelphia or Cincinnati Children's Hospital Medical Center from April 2013 to May 2018.³ Cystitis was assessed by reviewing the medical record and was defined as grade ≥ 2 : detectable BKPyV with urinary symptoms and visible hematuria.² The Institutional Review Boards at our 2 centers approved the study, and participants provided informed consent and assent. Eurofins Viracor (Lenexa, KS) previously tested blood and urine samples from subjects for BKPyV using a quantitative polymerase chain reaction (PCR).³ To test if genetic polymorphisms in viral defense proteins were associated with susceptibility to cystitis, genomic DNA was extracted from neutrophils collected pre-HSCT, to reflect recipient genome, using the QuickGene extraction system (Autogen, Holliston, MA, USA). The presence of a 29.5 kb deletion in the *APOBEC3* gene was assessed with a PCR breakpoint assay⁶ using a TaqMan PCR Master Mix kit (Qiagen, Hilden, Germany).

Briefly, separate PCR assays were performed with primers specific to the deletion (700bp product) and insertion (490bp product) alleles. These products were analyzed using a 1.5% agarose gel. Analyses of single nucleotide polymorphisms (SNP) in other viral defense genes (*TLR3*, melanoma differentiation-associated protein 5 [*MDA5*], retinoic acid-inducible gene I [*RIG1*], and interferon regulatory factor 3 [*IRF3*])^{5,7} were performed using TaqMan SNP genotyping mix and assays (Applied Biosystems, Waltham, MA, USA). To measure the expression of *APOBEC3A* and *APOBEC3B* genes, quantitative

PCR was performed on RNA extracted from mononuclear cells pre HSCT. Plasma APOBEC3B concentrations pre HSCT were measured using enzyme-linked immunosorbent assays (MyBioSource, San Diego, CA, USA), with limits of detection ranging from 0.625 to 20 ng/mL. We performed a correlative murine study to test if differential expression of TLR3 would explain the lower risk of cystitis in younger children. Wild-type murine formalin-fixed paraffin embedded bladder biopsies were sectioned at 4.5 μm onto positive-charged slides and baked at 60°C for 30 minutes (min). Slides were stained using the BenchMark DISCOVERY platform with a TLR3 antibody (Abcam, 62566) at 1:200 using a citrate HIER pretreatment and a 40 min incubation.

Continuous variables are presented as medians (interquartile range, IQR) and were examined with the Wilcoxon rank-sum test or signed-rank test. Categorical variables were examined with the χ^2 , Fisher's exact, or Cochran-Armitage test. The independent variable was defense protein polymorphisms. Cystitis was the primary outcome and secondary outcomes were BKPyV at 1-month post HSCT, separately defined as DNAemia (>0 copies/mL) or billionuria ($>10^9$ copies/mL). The study was designed to have 90% power to detect an Odds Ratio (OR) of 2.5 for cystitis in children with a deleted *APOBEC* allele compared to wild type. Analyses were performed using STATA (17.0), and a two-sided $P < 0.05$ was considered statistically significant. The 193 subjects had a median age of 10.2 years and 58.0% were male. The most common underlying diagnoses were malignancy (37%), bone marrow failure (27%), and immunodeficiency (21%). Conditioning included cyclophosphamide and busulfan in 56.5% and 43.5% of subjects, respectively (28.0% received both). Acute graft-versus-host disease developed in 38.3% of subjects. As we have previously reported,³ by 1-month post HSCT, 59/162 (36.4%) participants had BKPyV viruria ≥ 109 copies/mL (billionuria) and 73/185 (39.5%) had DNAemia >0 copies/mL. Grade ≥ 2 cystitis developed in 43/193 (22.3%) subjects at a median of 34 days (IQR: 25-54 days) post HSCT.³ The *APOBEC3* deletion polymorphism (Figure 1A) was detected in 28/174 (16.1%) recipients in their pre-HSCT DNA. The remaining 146/174 (83.9%) recipients did not have the deletion polymorphism and 19/193 (9.8%) could not be assessed. Median recipient pre-HSCT *APOBEC3A* expression – reported as the inverse of the delta cycle time – was significantly decreased in subjects with the deletion (0.054 [IQR: 0.052-0.055]) as compared to those with the wild type (0.058 [IQR: 0.056-0.060]) ($P < 0.0001$) (Figure 1B). Median *APOBEC3B* expression was decreased in subjects with the deletion (0.039 [IQR: 0.038-0.042]) as compared to those with the wild type (0.041 [IQR: 0.040-0.044]) ($P = 0.07$). Measuring protein expression

(Figure 1C), we observed that pre HSCT, median plasma APOBEC3B concentrations were significantly decreased in subjects with the deletion (0.27 ng/mL [IQR: 0-1.13 ng/mL]) compared to those without the deletion (0.89 ng/mL [IQR 0.65-1.52 ng/mL]) ($P=0.04$). The presence of the deletion was not associated with billionuria ($P=0.27$) or DNAemia ($P=0.45$) 1-month post HSCT. However, the *APOBEC3* deletion was more frequent among subjects who later developed cystitis (OR: 2.7, 95% Confidence Interval: 1.2-6.5; $P=0.02$). SNP in the viral sensor genes *MDA5*, *RIG1*, *IRF3*, and *TLR3* were also genotyped using recipient pre-HSCT samples (Table 1). Subjects with an A/A genotype at *TLR3* SNP rs5743305 had a lower risk of cystitis compared to those with an A/T or T/T genotype ($P=0.02$). The other 3 tested *TLR3* SNP were not

associated with cystitis. The tested *IRF3*, *MDA5*, and *RIG1* SNP were also not associated with cystitis. We had previously observed that older age was associated with a higher risk of cystitis.³ Of the 38 children <6 years of age in our cohort, only 5/38 (13.2%) developed cystitis and no child <4 years of age developed cystitis.

Expression of TLR3 in specific organs varies by age but the bladder has not been studied.^{7,8} We, therefore, hypothesized that age-dependent TLR3 expression may be associated with cystitis. Due to challenges in accessing bladder tissue from healthy children, we performed an immunohistochemistry analysis of TLR3 in bladders obtained from mice at day 3, day 21, and month 4 of age (Figure 2). TLR3 was highly expressed in all layers of the neonatal bladder. Expression




Figure 1. APOBEC3 deletion polymorphism. (A) A 29.5kb region spanning *APOBEC3A* and *APOBEC3B* is removed, forming a hybrid transcript that is distinguishable using a quantitative polymerase chain reaction (PCR) assay, the results of which are shown on a 1.5% agarose gel. The deletion polymorphism is associated with (B) a significant reduction in *APOBEC3A* expression ($P < 0.0001$) and reduced *APOBEC3B* expression ($P = 0.069$), and (C) significantly lower levels of plasma APOBEC3B concentration before allogeneic transplant ($P = 0.04$) (P values by Wilcoxon rank-sum).

remained constant in the urothelium but declined in other layers of the bladder with age, being largely absent in the submucosa of adult mice.

The mechanisms leading to cystitis are understudied. It is known that cellular immune responses are important to control BKPyV after HSCT and solid organ transplant.⁹ We hypothesized that polymorphisms in innate immune proteins would be associated with cystitis after HSCT. We observed that polymorphisms in defense (*APOBEC*) and sensor (*TLR3*) proteins were associated with susceptibility to cystitis. *APOBEC3* are DNA cytosine deaminases that provide antiviral defenses by mutating viral genomes.¹⁰ Importantly, others have shown that expression of BKPyV large T-antigen up-regulates *APOBEC3B* expression in cultured cells, supporting an important, although perhaps paradoxical, relationship between virus and host.¹¹ We es-

tablished that the *APOBEC* deletion was associated with reduced RNA and protein expression of *APOBEC3A* and *3B*, in agreement with a single prior study.¹² Homozygosity for the *APOBEC* deletion is infrequent in population studies, and we observed no homozygotes in our study.⁶ We then examined polymorphisms in other anti-viral defense proteins that occur with a clinically relevant minor allele frequency to identify additional relevant genetic variants. We identified an increased risk of cystitis associated with a functional SNP in *TLR3* (rs5743305), but no such variants in *MDA5*, *RIG1*, or *IRF3*. rs5743305 has been associated with infections in patients with leukemia¹³ and clearance of hepatitis B virus.¹⁴ This SNP is located in the promoter of *TLR3*. Work by others suggests reduced transcription from the variant allele in the setting of breast cancer, providing support that our observation is biologically relevant and

Table 1. Risk of hemorrhagic cystitis by immune defense protein genotype.

	Risk of hemorrhagic cystitis by genotype			P
<i>MDA5</i>				
rs35667974 HC	T/T, N=170 40 (23.5%)	T/C, N=5 1 (20.0%)	C/C, N=1 0 (0%)	0.61
rs1990760 HC	T/T, N=56 13 (23.2%)	T/C, N=73 17 (23.3%)	C/C, N=47 11 (23.4%)	0.98
rs3747517 HC	C/C, N=95 20 (21.1%)	T/C, N=63 15 (23.8%)	T/T, N=18 6 (33.3%)	0.30
rs35744605 HC	C/C, N=175 41 (23.4%)	A/C, N=1 0 (0%)	- -	1.0
<i>RIG1</i>				
rs9695310 HC	G/G, N=43 11 (25.6%)	G/C, N=91 19 (20.9%)	C/C, N=42 11 (26.2%)	0.95
rs3739674 HC	G/G, N=30 8 (26.7%)	G/C, N=77 16 (20.8%)	C/C, N=69 17 (24.6%)	0.98
<i>IRF3</i>				
rs7251 HC	C/C, N=65 16 (24.6%)	G/C, N=79 21 (26.6%)	G/G, N=27 3 (11.1%)	0.29
rs2304205 HC	A/A, N=87 23 (26.4%)	A/C, N=60 14 (23.3%)	C/C, N=21 3 (14.3%)	0.27
<i>TLR3</i>				
rs5743305 HC	T/T, N=71 22 (31.0%)	A/T, N=89 18 (20.2%)	A/A, N=16 1 (6.3%)	0.02
rs3775291 HC	C/C, N=93 20 (21.5%)	T/C, N=63 16 (25.4%)	T/T, N=20 5 (25.0%)	0.60
rs3775290 HC	C/C, N=97 21 (21.7%)	T/C, N=62 14 (22.6%)	T/T, N=17 6 (35.3%)	0.33
rs3775296 HC	C/C, N=116 23 (19.8%)	A/C, N=53 16 (30.2%)	A/A, N=7 2 (28.6%)	0.16

Data shown as number (N) (% with hemorrhagic cystitis [HC]) and P values calculated with Cochran-Armitage test for trend except for *MDA5* rs35744605 (Fisher exact test). Genotypes are ordered in the columns as homozygote-heterozygote-homozygote at each locus.




Figure 2. Expression of TLR3 in healthy mouse bladder tissue varies by age. Representative images of immunohistochemistry staining of TLR3 (brown staining indicates TLR3 expression and arrows show submucosa) in 2 neonatal (3 days old), 2 adolescent (21 days old), and 2 adult (4 months old) mice bladders. TLR3 is highly expressed in all layers of the neonatal bladder as demonstrated by the diffuse brown staining in the 3-day old mouse bladders. Expression remains constant in the urothelium but declines with age, as shown by the decreased intensity of the staining in the 21-day old and 4-month old mouse bladders. TLR3 was absent in the lamina propria and muscularis of the 21-day old and 4-month old mice (blue staining with arrows).

not a result of testing multiple comparisons.¹⁵

Cystitis rarely occurs in young children and older age was associated with an increased risk of cystitis in our cohort.³ Age-dependent expression of *TLR3* in the intestines of small children is associated with susceptibility to rotavirus.⁷ These data led us to speculate that bladder expression of TLR3 might also be age-dependent, and as younger children infrequently develop cystitis, that expression of TLR3 will decrease with age. We examined the expression of TLR3 in healthy mice at the equivalent of infant, adolescent, and adult ages, and observed decreases in submucosal bladder TLR3 expression in the older mice.

A strength of our study is the availability of samples collected prospectively from a large, clinically annotated cohort of children receiving HSCT, which we believe is the first such study ever undertaken. An important challenge in studying BKPyV-associated cystitis is the lack of an animal model, increasing the value of our carefully constructed human cohort. In summary, our findings offer the possibility of novel approaches to protect from BKPyV-associated cystitis, potentially by induction of relevant innate immune host defenses.

Authors

Sheyar Abdullah,¹ Anthony Sabulski,¹ Zahra Hudda,¹ Assem Ziady,¹ Nathan Luebbering,¹ Lucy Giordullo,¹ Elizabeth Odegard,² Jason T. Blackard,² Steve Kleiboeker,³ Michelle Altrich,³ Sonata Jodele,¹ Alix E. Seif,^{4,5} Stella M. Davies¹ and Benjamin L. Laskin^{5,6}

¹Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, and Department of Pediatrics, University of Cincinnati, Cincinnati, OH; ²Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH; ³Eurofins Viracor, Lenexa, KS; ⁴Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA; ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA and ⁶Division of Nephrology, Children's Hospital of Philadelphia, Philadelphia, PA, USA

Correspondence:

B.L. LASKIN - laskinb@chop.edu

<https://doi.org/10.3324/haematol.2024.286163>

Received: June 24, 2024.

Accepted: September 13, 2024.

Early view: September 19, 2024.

©2025 Ferrata Storti Foundation

Published under a CC BY-NC license 

Disclosures

SK and MA are employees of Eurofins Viracor who ran the BK polyomavirus PCR testing on blood and urine samples free of charge. All of the other authors have no conflicts of interest to disclose.

Contributions

SA designed research studies, conducted experiments, analyzed data, and wrote the manuscript. AS, SJ and AS designed research

studies, acquired and analyzed data, and critically reviewed the manuscript. ZH acquired and analyzed data, and critically reviewed the manuscript. AZ, EO and JB designed research studies, analyzed data, and critically reviewed the manuscript. NL designed research studies, conducted experiments, and analyzed data. LG acquired data. SK and MA conducted experiments, acquired data, and critically reviewed the manuscript. SD designed research studies, analyzed data, and wrote the manuscript. BL designed research studies, acquired and analyzed

data, and wrote the manuscript.

Funding

This work was supported by National Institutes of Health grant R01 DK125418 (to BLL and JTB).

Data-sharing statement

Requests for data can be sent by email to the corresponding author.

References

1. Dropulic LK, Jones RJ. Polyomavirus BK infection in blood and marrow transplant recipients. *Bone Marrow Transplant.* 2008;41(1):11-18.
2. Cesaro S, Dalianis T, Hanssen Rinaldo C, et al. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. *J Antimicrob Chemother.* 2018;73(1):12-21.
3. Laskin BL, Denburg MR, Furth SL, et al. The natural history of BK polyomavirus and the host immune response after stem cell transplantation. *Clin Infect Dis.* 2020;71(12):3044-3054.
4. Peretti A, Geoghegan EM, Pastrana DV, et al. Characterization of BK polyomaviruses from kidney transplant recipients suggests a role for APOBEC3 in driving in-host virus evolution. *Cell Host Microbe.* 2018;23(5):628-635.
5. Redondo N, Rodriguez-Goncer I, Parra P, et al. Genetic polymorphisms in TLR3, IL10 and CD209 influence the risk of BK polyomavirus infection after kidney transplantation. *Sci Rep.* 2022;12(1):11338.
6. Kidd JM, Newman TL, Tuzun E, Kaul R, Eichler EE. Population stratification of a common APOBEC gene deletion polymorphism. *PLoS Genet.* 2007;3(4):e63.
7. Pott J, Stockinger S, Torow N, et al. Age-dependent TLR3 expression of the intestinal epithelium contributes to rotavirus susceptibility. *PLoS Pathog.* 2012;8(5):e1002670.
8. Iram N, Mildner M, Prior M, et al. Age-related changes in expression and function of Toll-like receptors in human skin. *Development.* 2012;139(22):4210-4219.
9. Espada E, Cheng MP, Kim HT, et al. BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. *Blood Adv.* 2020;4(9):1881-1893.
10. Stavrou S, Ross SR. APOBEC3 proteins in viral immunity. *J Immunol.* 2015;195(10):4565-4570.
11. Verhalen B, Starrett GJ, Harris RS, Jiang M. Functional upregulation of the DNA cytosine deaminase APOBEC3B by polyomaviruses. *J Virol.* 2016;90(14):6379-6386.
12. Klonowska K, Kluzniak W, Rusak B, et al. The 30 kb deletion in the APOBEC3 cluster decreases APOBEC3A and APOBEC3B expression and creates a transcriptionally active hybrid gene but does not associate with breast cancer in the European population. *Oncotarget.* 2017;8(44):76357-76374.
13. Wicherska-Pawlowska K, Bogunia-Kubik K, Kuszczak B, et al. Polymorphisms in the genes coding for TLRs, NLRs and RLRs are associated with clinical parameters of patients with acute myeloid leukemia. *Int J Mol Sci.* 2022;23(17):9593.
14. Fischer J, Koukouloti E, Schott E, et al. Polymorphisms in the Toll-like receptor 3 (TLR3) gene are associated with the natural course of hepatitis B virus infection in Caucasian population. *Sci Rep.* 2018;8(1):12737.
15. Fan L, Zhou P, Chen AX, Liu GY, Yu KD, Shao ZM. Toll-like receptor 3 -926T>A increased the risk of breast cancer through decreased transcriptional activity. *Oncoimmunology.* 2019;8(12):e1673126.